脯氨酰羟化酶与低氧诱导因子在慢性阻塞性肺疾病患者中的表达及临床意义  

The expression and clinical significance of PHDs and HIF in patient with COPD

作　　者：邱锦帆[1] 于化鹏[1] 方思[1] 杨智[1] 

机构地区：[1]南方医科大学珠江医院呼吸内科,广州510280

出　　处：《国际呼吸杂志》2016年第19期1481-1485,共5页International Journal of Respiration

摘　　要：COPD是一种以进行性发展的气流受限为特征、可预防的肺部疾病。由于呼吸功能的损伤,COPD患者通常合并缺氧。低氧诱导因子（hypoxia-induciblefactor,HIF）是一种缺氧状态下的关键转录因子。但在其进行代偿调节的同时,也会给机体带来病理性损害,如低氧性肺动脉高压、促进肿瘤生长等。脯氨酰羟化酶可直接调控HIF,是缺氧反应的真正触发器,一定程度上预防了COPD合并肺动脉高压、肺癌的发生。Chronic obstructive pulmonary disease（COPD） is a pulmonary disease by persistent airflow limitation which showing progressive development and can be prevented. Hypoxia is common complication of COPD because of diminished respiratory function. Hypoxia-induced factor （HIF） is a nuclear transcription factor that plays an important role in hypoxic state. However, the compensatory function of hypoxia was mediated by HIF while causing pathological damage, such as hypoxic pulmonary hypertension and tumor. Prolyl hydroxylase （PHDs） is the real trigger of hypoxic reaction which can directly control the HIF by prompted the hydroxylation of HIF. To some extent, PHDs will prevent the complications of COPD include pulmonary hypertension and lung cancer.

关 键 词：慢性阻塞性肺疾病 低氧诱导因子 脯氨酰羟化酶 肺动脉高压 肿瘤 

分 类 号：R563.9[医药卫生—呼吸系统]